{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,22]],"date-time":"2026-02-22T03:35:03Z","timestamp":1771731303894,"version":"3.50.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2016,10,6]],"date-time":"2016-10-06T00:00:00Z","timestamp":1475712000000},"content-version":"vor","delay-in-days":1073,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4,1]]},"DOI":"10.1093\/ndt\/gft424","type":"journal-article","created":{"date-parts":[[2013,10,29]],"date-time":"2013-10-29T22:50:48Z","timestamp":1383087048000},"page":"843-850","source":"Crossref","is-referenced-by-count":32,"title":["The FIND-CKD study\u2014a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale"],"prefix":"10.1093","volume":"29","author":[{"given":"Iain C.","family":"Macdougall","sequence":"first","affiliation":[{"name":"Department of Renal Medicine, King's College Hospital, Denmark Hill, London, UK"}]},{"given":"Andreas","family":"Bock","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Kantonsspital Aarau, Aarau, Switzerland"}]},{"given":"Fernando","family":"Carrera","sequence":"additional","affiliation":[{"name":"Eurodial, DaVita. Leiria, Leiria, Portugal"}]},{"given":"Kai-Uwe","family":"Eckardt","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Hypertension, University of Erlangen-N\u00fcrnberg, Erlangen, Germany"}]},{"given":"Carlo","family":"Gaillard","sequence":"additional","affiliation":[{"name":"Department of Nephrology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands"}]},{"given":"David","family":"Van Wyck","sequence":"additional","affiliation":[{"name":"DaVita Healthcare Partners Inc., Denver, CO, USA"}]},{"given":"Bernard","family":"Roubert","sequence":"additional","affiliation":[{"name":"Vifor Pharma Ltd, Glattbrugg, Switzerland"}]},{"given":"Timothy","family":"Cushway","sequence":"additional","affiliation":[{"name":"Vifor Pharma Ltd, Glattbrugg, Switzerland"}]},{"given":"Simon D.","family":"Roger","sequence":"additional","affiliation":[{"name":"Renal Research, Gosford, NSW, Australia"}]},{"name":"on Behalf of the FIND-CKD Study Investigators","sequence":"additional","affiliation":[]}],"member":"286","published-online":{"date-parts":[[2013,10,29]]},"reference":[{"key":"key\n\t\t\t\t20180328173621_GFT424C1","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180328173621_GFT424C2","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1093\/ndt\/gfl195","article-title":"Screening for early chronic kidney disease \u2013 what method fits best?","volume":"21","author":"de Jong","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180328173621_GFT424C3","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1681\/ASN.2005121273","article-title":"International comparison of the relationship of chronic kidney disease prevalence and ESRD risk","volume":"17","author":"Hallan","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180328173621_GFT424C4","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1185\/030079904X2763","article-title":"The prevalence of anemia in patients with chronic kidney disease","volume":"20","author":"McClellan","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"key\n\t\t\t\t20180328173621_GFT424C5","first-page":"ii1","article-title":"European best practice guidelines for the management of anaemia in patients with chronic renal failure","volume":"19","author":"Locatelli","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180328173621_GFT424C6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1053\/j.ajkd.2009.12.030","article-title":"Molecular mechanisms of hepcidin regulation: implications for the anemia of CKD","volume":"55","author":"Babitt","year":"2010","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180328173621_GFT424C7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ndt\/17.suppl_11.35","article-title":"Non-erythropoietin-based anaemia management in chronic kidney disease","volume":"17","author":"H\u00f6rl","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180328173621_GFT424C8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0272-6386(95)90151-5","article-title":"Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation","volume":"26","author":"Fishbane","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180328173621_GFT424C9","first-page":"2070","article-title":"Importance of iron supply for erythropoietin therapy","volume":"10","author":"Sunder-Plassmann","year":"1995","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180328173621_GFT424C10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10741-012-9342-y","article-title":"Iron deficiency anemia in heart failure","volume":"18","author":"Arora","year":"2013","journal-title":"Heart Fail Rev"},{"key":"key\n\t\t\t\t20180328173621_GFT424C11","doi-asserted-by":"crossref","first-page":"568S","DOI":"10.1093\/jn\/131.2.568S","article-title":"Iron biology in immune function, muscle metabolism and neuronal functioning","volume":"131","author":"Beard","year":"2001","journal-title":"J Nutr"},{"key":"key\n\t\t\t\t20180328173621_GFT424C12","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa062276","article-title":"Normalization of hemoglobin level in patients with chronic kidney disease and anemia","volume":"335","author":"Drueke","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328173621_GFT424C13","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328173621_GFT424C14","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/ki.2008.295","article-title":"Secondary analysis of the CHOIR trial epoetin-\u03b1 dose and achieved hemoglobin outcomes","volume":"74","author":"Szczech","year":"2008","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180328173621_GFT424C15","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1056\/NEJMoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"New Engl J Med"},{"key":"key\n\t\t\t\t20180328173621_GFT424C16","first-page":"292","article-title":"Clinical practice guideline for anemia in chronic kidney disease","volume":"2","author":"Kidney Disease Improving Global Outcomes (KDIGO)","year":"2012","journal-title":"Kid Int Suppl"},{"key":"key\n\t\t\t\t20180328173621_GFT424C17","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1093\/ndt\/gfq613","article-title":"A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients","volume":"26","author":"Qunibi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180328173621_GFT424C18","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1681\/ASN.2007101156","article-title":"Ferumoxytol for treating iron deficiency anemia in CKD","volume":"19","author":"Spinowitz","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180328173621_GFT424C19","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1111\/j.1523-1755.2005.00758.x","article-title":"A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD","volume":"68","author":"Van Wyck","year":"2005","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180328173621_GFT424C20","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/ndt\/gfs528","article-title":"Intravenous ferric carboxymaltose versus standard medical care in the treatment of iron deficiency anemia in patients with chronic kidney disease: a randomized, active-controlled, multi-center study","volume":"28","author":"Charytan","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180328173621_GFT424C21","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/ndt\/gfi087","article-title":"Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients","volume":"21","author":"Mircescu","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180328173621_GFT424C22","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000096174","article-title":"A randomized controlled trial of oral versus intravenous iron in chronic kidney disease","volume":"26","author":"Agarwal","year":"2006","journal-title":"Am J Nephrol"},{"key":"key\n\t\t\t\t20180328173621_GFT424C23","first-page":"S11","article-title":"Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease","volume":"47","author":"Kidney Disease Outcomes Quality Initiative (KDOQI)","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180328173621_GFT424C24","article-title":"Clinical guideline 114. Anaemia management in people with chronic kidney disease","author":"National Institute for Health and Clinical Excellence (NICE)","year":"2011"},{"key":"key\n\t\t\t\t20180328173621_GFT424C25","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.2146\/ajhp110231","article-title":"Intravenous versus oral iron for treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease","volume":"69","author":"Liles","year":"2012","journal-title":"Am J Health Syst Pharm"},{"key":"key\n\t\t\t\t20180328173621_GFT424C26","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1053\/j.ajkd.2008.05.033","article-title":"Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis","volume":"52","author":"Rosen-Zvi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180328173621_GFT424C27","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180328173621_GFT424C28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jacc.2007.09.036","article-title":"Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: a randomized, controlled, observer-blinded trial","volume":"51","author":"Okonko","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180328173621_GFT424C29","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1093\/ndt\/gft033","article-title":"Kidney disease: improving global outcomes guidelines on anaemia management in chronic kidney disease: a european renal best practice position statement","volume":"28","author":"Locatelli","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180328173621_GFT424C30","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1185\/03007990903512461","article-title":"Iron supplementation in the non-dialysis chronic kidney disease (ND-CKD) patient: oral or intravenous?","volume":"26","author":"Macdougall","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"key\n\t\t\t\t20180328173621_GFT424C31","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1525-139X.2007.00420.x","article-title":"Upper limit of serum ferritin: misinterpretation of the 2006 KDOQI anemia guidelines","volume":"21","author":"Fishbane","year":"2008","journal-title":"Semin Dial"},{"key":"key\n\t\t\t\t20180328173621_GFT424C32","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1053\/ajkd.2001.25203","article-title":"Optimizing erythropoietin therapy in hemodialysis patients","volume":"38","author":"Richardson","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180328173621_GFT424C33","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1159\/000045574","article-title":"Improved response to erythropoietin therapy with long-term continuous iron supplementation","volume":"84","author":"Descombes","year":"2000","journal-title":"Nephron"},{"key":"key\n\t\t\t\t20180328173621_GFT424C34","author":"FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of Erythropoiesis-Stimulating Agents (ESAs) in chronic kidney disease"},{"key":"key\n\t\t\t\t20180328173621_GFT424C35","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/0003-4819-130-6-199903160-00002","article-title":"A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. modification of diet in renal disease study group","volume":"130","author":"Levey","year":"1999","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180328173621_GFT424C36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/ndt\/gfn653","article-title":"Anaemia management in patients with chronic kidney disease: a position statement by the anaemia working group of european renal best practice (ERBP)","volume":"24","author":"Locatelli","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180328173621_GFT424C37","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2215\/CJN.01490506","article-title":"Assessing iron status: beyond serum ferritin and transferrin saturation","volume":"1","author":"Wish","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180328173621_GFT424C38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1056\/NEJMp0912328","article-title":"Erythropoiesis-stimulating agents \u2013 time for a reevaluation","volume":"362","author":"Unger","year":"2010","journal-title":"New Engl J Med"},{"key":"key\n\t\t\t\t20180328173621_GFT424C39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1681\/ASN.2009111127","article-title":"Does TREAT give the boot to ESAs in the treatment of CKD in anemia?","volume":"21","author":"Singh","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180328173621_GFT424C40","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2215\/CJN.00020112","article-title":"Effect of red cell transfusions on future kidney transplantation","volume":"8","author":"Obrador","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180328173621_GFT424C41","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1093\/ndt\/gfs575","article-title":"How important is transfusion avoidance in 2013?","volume":"28","author":"Macdougall","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"key\n\t\t\t\t20180328173621_GFT424C42","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1210\/jc.2008-2396","article-title":"FGF23 Elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study","volume":"94","author":"Schouten","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t20180328173621_GFT424C43","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/j.1523-1755.2004.00648.x","article-title":"Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease","volume":"65","author":"Agarwal","year":"2004","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20180328173621_GFT424C44","doi-asserted-by":"crossref","first-page":"114","DOI":"10.2215\/CJN.06020710","article-title":"Proteinuria induced by parenteral iron in chronic kidney disease \u2013 a comparative randomized controlled trial","volume":"6","author":"Agarwal","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"key\n\t\t\t\t20180328173621_GFT424C45","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1053\/j.ajkd.2008.09.001","article-title":"Economic considerations in a changing anemia environment","volume":"52","author":"Pizzi","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"key\n\t\t\t\t20180328173621_GFT424C46","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3111\/13696998.2011.639823","article-title":"Evaluation of cost savings with ferric carboxymaltose in anemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective","volume":"15","author":"Luporsi","year":"2012","journal-title":"J Med Econ"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/29\/4\/843\/17171998\/gft424.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,4,2]],"date-time":"2018-04-02T10:41:36Z","timestamp":1522665696000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/29\/4\/843\/1929695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,29]]},"references-count":46,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,10,29]]},"published-print":{"date-parts":[[2014,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gft424","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,4]]},"published":{"date-parts":[[2013,10,29]]}}}